Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma
IMCgp100, a novel immune-based treatment, demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, which is nearly double the historical expectations for patients with the disease.
Source: OncLive